RESUMEN
Pulmonary carcinoid tumors are uncommon neuroendocrine tumors that rarely metastasize to the skin. We report the case of a 71-year-old woman with a longstanding history of primary atypical pulmonary carcinoid tumor who presented with a new tender cutaneous nodule. Immunostaining of the nodule was consistent with metastatic atypical carcinoid tumor of the skin including positive staining for neuroendocrine markers chromogranin and synaptophysin. Dermatologists should consider cutaneous neuroendocrine metastasis when evaluating new nodules in patients with stable pulmonary carcinoid tumors or in those with concomitant concerning respiratory symptoms.
Asunto(s)
Tumor Carcinoide/secundario , Neoplasias Pulmonares/patología , Neoplasias Cutáneas/secundario , Tejido Subcutáneo , Anciano , Femenino , HumanosAsunto(s)
Enfermedades del Cabello , Personas Transgénero , Transexualidad , Femenino , Identidad de Género , Cabello , Humanos , MasculinoAsunto(s)
Ansiedad , Cuero Cabelludo , Alopecia/diagnóstico , Ansiedad/etiología , Humanos , Percepción , FotograbarAsunto(s)
Cuero Cabelludo , Realidad Virtual , Estudios Cruzados , Humanos , Inyecciones , Manejo del DolorAsunto(s)
Liquen Plano , Alopecia , Humanos , Liquen Plano/radioterapia , Proyectos Piloto , Estudios Prospectivos , Cuero CabelludoAsunto(s)
Alopecia Areata , Dermatitis Atópica , Psoriasis , Alopecia Areata/inducido químicamente , Anticuerpos Monoclonales Humanizados/efectos adversos , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/tratamiento farmacológico , Humanos , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológicoAsunto(s)
Alopecia , Cuero Cabelludo , Alopecia/diagnóstico , Ansiedad/diagnóstico , Humanos , Percepción , FotograbarAsunto(s)
COVID-19 , Tricotilomanía , Estudios Transversales , Humanos , Pandemias , SARS-CoV-2 , EstudiantesAsunto(s)
Alopecia/dietoterapia , Seguridad de Productos para el Consumidor/normas , Suplementos Dietéticos/efectos adversos , Seguridad del Paciente/normas , Etiquetado de Productos/normas , Suplementos Dietéticos/normas , Humanos , Estados Unidos , United States Food and Drug Administration/normasAsunto(s)
Anomalías Inducidas por Medicamentos/prevención & control , COVID-19 , Fármacos Dermatológicos/efectos adversos , Isotretinoína/efectos adversos , Formulación de Políticas , Pruebas de Embarazo , Gestión de Riesgos , Telemedicina , Teratógenos , Anomalías Inducidas por Medicamentos/etiología , Femenino , Humanos , Embarazo , Medición de Riesgo , Factores de Riesgo , UrinálisisAsunto(s)
Quemaduras/complicaciones , Cicatriz/cirugía , Current Procedural Terminology , Terapia por Láser/economía , Heridas y Lesiones/complicaciones , Adulto , Factores de Edad , Superficie Corporal , Niño , Cicatriz/diagnóstico , Cicatriz/economía , Cicatriz/etiología , Humanos , Lactante , Reembolso de Seguro de Salud/normas , Terapia por Láser/instrumentación , Láseres de Gas/uso terapéutico , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
INTRODUCTION: Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. CASE PRESENTATION: Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. DISCUSSION: Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.
RESUMEN
Treatment options for hair loss have traditionally been limited to topical and systemic therapies. Systemic therapies for inflammatory hair disorders are often immunosuppressive, and systemic treatment of androgenetic hair loss can cause undesired effects on sexual and reproductive health. Topical agents have a favorable side effect profile compared with systemic therapies, but many topicals have poor transcutaneous absorption, limiting their concentration and action at follicular targets in the dermis.